Search details
1.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Article
in English
| MEDLINE | ID: mdl-37506339
2.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Article
in English
| MEDLINE | ID: mdl-38031761
3.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Blood
; 134(16): 1337-1345, 2019 10 17.
Article
in English
| MEDLINE | ID: mdl-31484647
4.
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
Eur J Haematol
; 100(3): 264-272, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29226472
5.
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
EClinicalMedicine
; 73: 102642, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38841711
6.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia
; 38(5): 1072-1080, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38548962
7.
Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease.
Cancers (Basel)
; 15(16)2023 Aug 08.
Article
in English
| MEDLINE | ID: mdl-37627050
8.
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
Leukemia
; 37(3): 659-669, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36596983
9.
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): e844-e852, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35688793
10.
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sci Rep
; 12(1): 13057, 2022 07 29.
Article
in English
| MEDLINE | ID: mdl-35906470
11.
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
J Mol Diagn
; 22(10): 1217-1224, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32688056
12.
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality.
Blood Cancer J
; 10(10): 103, 2020 10 19.
Article
in English
| MEDLINE | ID: mdl-33077708
13.
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
Front Pharmacol
; 10: 1340, 2019.
Article
in English
| MEDLINE | ID: mdl-31824308
14.
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sci Rep
; 14(1): 7400, 2024 Mar 28.
Article
in English
| MEDLINE | ID: mdl-38548834
15.
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Blood Cancer J
; 8(10): 91, 2018 12 02.
Article
in English
| MEDLINE | ID: mdl-30504932
16.
Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia.
Leuk Res
; 121: 106923, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35933910
17.
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.
PLoS One
; 12(7): e0181366, 2017.
Article
in English
| MEDLINE | ID: mdl-28704552
18.
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
Haematologica
; 91(5): 621-7, 2006 May.
Article
in English
| MEDLINE | ID: mdl-16627253
19.
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.
Clinicoecon Outcomes Res
; 8: 475-484, 2016.
Article
in English
| MEDLINE | ID: mdl-27703384
20.
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Cancer Med
; 4(7): 995-1002, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25756742